Overview

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborator:

Shanghai Clinical Research Center

Treatments:

Venetoclax